药学研究
藥學研究
약학연구
Journal of Pharmaceutical Research
2015年
10期
608-610
,共3页
糖尿病肾病%瑞舒伐他汀%前列地尔注射液
糖尿病腎病%瑞舒伐他汀%前列地爾註射液
당뇨병신병%서서벌타정%전렬지이주사액
Diabetic nephropathy%Rosuvastatin%Alprostadil Injection
目的：观察瑞舒伐他汀联合前列地尔治疗糖尿病肾病的临床疗效。方法90例糖尿病肾病患者随机分为两组。前列地尔组45例，给予前列地尔注射液20μg，静脉滴注，每天1次；联合用药组45例，给予瑞舒伐他汀与前列地尔注射液，瑞舒伐他汀10 mg，口服，每天1次，前列地尔注射液用法同前组。两组疗程均为24周，观察两组治疗前后的尿蛋白排泄率、24 h 尿蛋白、血肌酐、血脂等指标。结果治疗后，两组尿蛋白排泄率与24 h 尿蛋白均降低（P ﹤0.01）。联合用药组尿蛋白排泄率、24 h 尿蛋白降低幅度大于前列地尔组（P ﹤0.01），两组血肌酐与空腹血糖均下降，差异无显著意义（P ﹥0.05）。两组血脂和血压降低均有所改善（P ﹤0.01），联合用药组血脂改变程度优于前列地尔组（P ﹤0.01）。结论瑞舒伐他汀联合前列地尔治疗糖尿病肾病，对肾脏保护有协同作用。
目的：觀察瑞舒伐他汀聯閤前列地爾治療糖尿病腎病的臨床療效。方法90例糖尿病腎病患者隨機分為兩組。前列地爾組45例，給予前列地爾註射液20μg，靜脈滴註，每天1次；聯閤用藥組45例，給予瑞舒伐他汀與前列地爾註射液，瑞舒伐他汀10 mg，口服，每天1次，前列地爾註射液用法同前組。兩組療程均為24週，觀察兩組治療前後的尿蛋白排洩率、24 h 尿蛋白、血肌酐、血脂等指標。結果治療後，兩組尿蛋白排洩率與24 h 尿蛋白均降低（P ﹤0.01）。聯閤用藥組尿蛋白排洩率、24 h 尿蛋白降低幅度大于前列地爾組（P ﹤0.01），兩組血肌酐與空腹血糖均下降，差異無顯著意義（P ﹥0.05）。兩組血脂和血壓降低均有所改善（P ﹤0.01），聯閤用藥組血脂改變程度優于前列地爾組（P ﹤0.01）。結論瑞舒伐他汀聯閤前列地爾治療糖尿病腎病，對腎髒保護有協同作用。
목적：관찰서서벌타정연합전렬지이치료당뇨병신병적림상료효。방법90례당뇨병신병환자수궤분위량조。전렬지이조45례，급여전렬지이주사액20μg，정맥적주，매천1차；연합용약조45례，급여서서벌타정여전렬지이주사액，서서벌타정10 mg，구복，매천1차，전렬지이주사액용법동전조。량조료정균위24주，관찰량조치료전후적뇨단백배설솔、24 h 뇨단백、혈기항、혈지등지표。결과치료후，량조뇨단백배설솔여24 h 뇨단백균강저（P ﹤0.01）。연합용약조뇨단백배설솔、24 h 뇨단백강저폭도대우전렬지이조（P ﹤0.01），량조혈기항여공복혈당균하강，차이무현저의의（P ﹥0.05）。량조혈지화혈압강저균유소개선（P ﹤0.01），연합용약조혈지개변정도우우전렬지이조（P ﹤0.01）。결론서서벌타정연합전렬지이치료당뇨병신병，대신장보호유협동작용。
Objective To observe the clinical efficacy of Rosuvastatin combined with Alprostadil Injection in the treat-ment of diabetic nephropathy. Methods Ninety patients were randomly divided into two groups:45 patients of alprostadil group were treated with Alprostadil Injection 20 μg,qd;45 patients in combination therapy group were treated with Rosuvas-tatin 10 mg,po,qd and Alprostadil Injection 20 μg,qd. All patients in each group received the correlative therapy for 24 weeks. The urinary albumin excretion rate(UAER),serum creatinine(Scr),blood lipid were observed and recorded before and after the treatment. Results After the treatment,UAER,24 h urine protein decreased in two groups(P ﹤ 0. 01). But the UAER,24 h urine protein decreased in combination therapy group which was better than those in alprostadil group(P ﹤0. 01). The Scr and fasting blood glucose decreased in two groups with no significant difference among them(P ﹥ 0. 05). The blood lipid was improved in two groups(P ﹤ 0. 01),especially in combination therapy group. Conclusion Rosuvastatin and Alprostadil Injection in combination therapy were superior to monotherapy in the treatment of diabetic nephropathy.
